Necker Institute
Paris, FRANCE
I lead IMMEDIAB research team at the Necker Institute (Paris), a research team dedicated to deciphering the cellular and molecular mechanisms governing immune–metabolic cross-talk in health and type 2 diabetes (T2D). Our research explores how immune and metabolic systems coordinate to maintain tissue homeostasis and adapt to environmental challenges.
We investigate how maladaptive immune responses—particularly dysregulated macrophage activation—disrupt this equilibrium, promoting insulin resistance, impaired glucose tolerance, and defective insulin secretion. Our work has identified novel regulatory pathways that control macrophage effector functions and increase susceptibility to T2D by altering both systemic insulin sensitivity and pancreatic β-cell function in humans and mouse models.
By integrating mechanistic approaches with translational studies in human cohorts, our team provides new insights into tissue inflammation in obesity and diabetes. Ultimately, our goal is to identify innovative therapeutic targets that restore immune–metabolic balance and improve metabolic health.
http://www.institut-necker-enfants-malades.fr/en-gb/node/2898
https://www.immediab.com
Disclosure information not submitted.
SY70-03 - Reclassifying Type 2 Diabetes Through Immune System Architecture
Tuesday, June 16, 2026
11:45 AM - 12:15 PM CT